Shanghai Bao Pharmaceuticals jumps after China clinical trial nod for gastroscopy product
12/03/2026 05:50
** Shares of Shanghai Bao Pharmaceuticals 2659.HK jump 6.4% to HK$126.6 ** Pharma products developer said National Medical Products Administration has approved its "KJ101" to conduct clinical trials in China for dissolution and removal of gastric mucus during gastroscopy ** KJ101 is a recombinant human chymotrypsin developed through synthetic biology in China by the company to fully replace animal-derived products - Co ** YTD, stock up 54%, while Hang Seng Biotech Index .HSBIO down 0.7% (Reporting by Donny Kwok) ((donny.kwok@thomsonreuters.com))
Recent news on Shanghai Bao Pharmaceuticals Co
See all newsBrief: Shanghai Bao Pharmaceuticals Says U.S. FDA Approves IND For Subcutaneous Infusion Of BJ007 For Injection
Brief: Shanghai Bao Pharmaceuticals Says NMPA Accepts NDA For KJL03 For Injection
Brief: Shanghai Bao Pharmaceuticals Says NMPA Approves Human Hyaluronidase For Injection For Marketing
Shanghai Bao at nearly 4-week high on China regulator nod to new product
Brief: Shanghai Bao Pharmaceuticals Proposes To Elect Liu Yanjun, Wang Zheng, Li Cui As Executive Directors